Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more
Hemogenyx Pharmaceuticals Plc (HOPHF) - Total Assets
Latest total assets as of June 2025: $4.26 Million USD
Based on the latest financial reports, Hemogenyx Pharmaceuticals Plc (HOPHF) holds total assets worth $4.26 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hemogenyx Pharmaceuticals Plc - Total Assets Trend (2014–2024)
This chart illustrates how Hemogenyx Pharmaceuticals Plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hemogenyx Pharmaceuticals Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Hemogenyx Pharmaceuticals Plc's total assets of $4.26 Million consist of 19.9% current assets and 80.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.8% |
| Accounts Receivable | $3.77K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $477.40K | 11.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Hemogenyx Pharmaceuticals Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hemogenyx Pharmaceuticals Plc's current assets represent 19.9% of total assets in 2024, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 14.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 11.3% of total assets.
Hemogenyx Pharmaceuticals Plc Competitors by Total Assets
Key competitors of Hemogenyx Pharmaceuticals Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Hemogenyx Pharmaceuticals Plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hemogenyx Pharmaceuticals Plc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hemogenyx Pharmaceuticals Plc is currently not profitable relative to its asset base.
Hemogenyx Pharmaceuticals Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.43 | 4.38 | 15.75 |
| Quick Ratio | 0.43 | 4.38 | 15.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.03 Million | $ 1.91 Million | $ 3.18 Million |
Hemogenyx Pharmaceuticals Plc - Advanced Valuation Insights
This section examines the relationship between Hemogenyx Pharmaceuticals Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.39 |
| Latest Market Cap to Assets Ratio | 1.06 |
| Asset Growth Rate (YoY) | -31.0% |
| Total Assets | $4.21 Million |
| Market Capitalization | $4.48 Million USD |
Valuation Analysis
Above Book Valuation: The market values Hemogenyx Pharmaceuticals Plc's assets above their book value (1.06 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Hemogenyx Pharmaceuticals Plc's assets decreased by 31.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hemogenyx Pharmaceuticals Plc (2014–2024)
The table below shows the annual total assets of Hemogenyx Pharmaceuticals Plc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.21 Million | -31.02% |
| 2023-12-31 | $6.11 Million | -13.91% |
| 2022-12-31 | $7.09 Million | -16.76% |
| 2021-12-31 | $8.52 Million | +219.77% |
| 2020-12-31 | $2.66 Million | +153.79% |
| 2019-12-31 | $1.05 Million | -54.34% |
| 2018-12-31 | $2.30 Million | -4.01% |
| 2017-12-31 | $2.40 Million | +128.71% |
| 2016-12-31 | $1.05 Million | +222.62% |
| 2015-12-31 | $324.65K | +642.40% |
| 2014-12-31 | $43.73K | -- |